Business Description
Savara Inc
NAICS : 325412
SIC : 2834
ISIN : US8051111016
Description
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.37 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.5 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 49.5 | |||||
| 3-Year EPS without NRI Growth Rate | 41.9 | |||||
| 3-Year FCF Growth Rate | 41.5 | |||||
| 3-Year Book Growth Rate | -22.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 85.67 | |||||
| 9-Day RSI | 74.51 | |||||
| 14-Day RSI | 67.68 | |||||
| 6-1 Month Momentum % | 25.42 | |||||
| 12-1 Month Momentum % | 129.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 18.98 | |||||
| Quick Ratio | 18.98 | |||||
| Cash Ratio | 18.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -30.9 | |||||
| Shareholder Yield % | 0.08 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -43.91 | |||||
| ROA % | -34.01 | |||||
| ROIC % | -404.76 | |||||
| ROC (Joel Greenblatt) % | -38148.28 | |||||
| ROCE % | -38.7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.84 | |||||
| Price-to-Tangible-Book | 4.12 | |||||
| EV-to-EBIT | -7.91 | |||||
| EV-to-Forward-EBIT | -6.73 | |||||
| EV-to-EBITDA | -7.93 | |||||
| EV-to-FCF | -9.49 | |||||
| Price-to-Net-Current-Asset-Value | 4.2 | |||||
| Price-to-Net-Cash | 4.24 | |||||
| Earnings Yield (Greenblatt) % | -12.64 | |||||
| FCF Yield % | -7.88 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SVRA
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Savara Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.31 | ||
| Beta | 0.5 | ||
| Volatility % | 84.47 | ||
| 14-Day RSI | 67.68 | ||
| 14-Day ATR ($) | 0.193891 | ||
| 20-Day SMA ($) | 3.76425 | ||
| 12-1 Month Momentum % | 129.81 | ||
| 52-Week Range ($) | 1.42 - 4.27 | ||
| Shares Outstanding (Mil) | 135.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Savara Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Savara Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Savara Inc Frequently Asked Questions
What is Savara Inc(SVRA)'s stock price today?
The current price of SVRA is $4.16. The 52 week high of SVRA is $4.27 and 52 week low is $1.42.
When is next earnings date of Savara Inc(SVRA)?
The next earnings date of Savara Inc(SVRA) is 2024-03-29 Est..
Does Savara Inc(SVRA) pay dividends? If so, how much?
Savara Inc(SVRA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers